Welcome to our dedicated page for Neuronetics SEC filings (Ticker: STIM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Neuronetics, Inc. filings document the public reporting record for a Nasdaq-listed medical technology and healthcare company with common stock traded under STIM. Recent Form 8-K reports furnish operating results, investor presentation materials, executive appointments and retirements, compensation arrangements, restructuring charges, and material agreements tied to credit facilities and registration rights.
The company’s proxy materials describe annual meeting voting matters, director elections, auditor ratification, advisory executive compensation votes, and equity incentive plan approvals. Together with event reports, the filings disclose governance procedures, capital-structure matters, Nasdaq-listed security information, and contractual obligations associated with Neuronetics’ medical device and clinic-services operations.
Neuronetics, Inc. filed an initial insider ownership report for President and CEO Daniel L. Reuvers. This Form 3 identifies him as an executive officer but does not show any stock transactions or option exercises. It serves as a baseline disclosure of his status as a reporting insider under SEC rules.
Neuronetics, Inc. insider activity: 10% owner Jorey Chernett purchased 169,472 shares of Neuronetics common stock in an open-market transaction at a weighted average price of $1.41 per share. The footnote states the trades occurred in multiple transactions between $1.36 and $1.44 per share, rounded to the nearest cent.
Following this purchase, Chernett directly holds 8,743,276 Neuronetics shares. The filing notes he can provide detailed breakdowns of the number of shares bought at each specific price upon request by the company, its security holders, or the SEC staff.
Neuronetics, Inc. 10% owner Jorey Chernett reported significant open-market buying of the company’s common stock. On March 18, 2026, he purchased 607,400 shares at a weighted average price of $1.35 per share in multiple trades. On March 19, 2026, he bought an additional 450,000 shares at a weighted average price of $1.33 per share, also across multiple transactions. Following these purchases, Chernett directly owns 8,573,804 shares of Neuronetics common stock.
STIM submitted a Form 144 notice to sell 16,005 shares of Common Stock tied to Restricted Stock Vesting with an effective date of 12/31/2025.
The filing also discloses recent dispositions by William A. Macan: 3,485 shares on 02/10/2026, 14,120 shares on 02/12/2026, 3,427 shares on 02/26/2026, and 609 shares on 03/04/2026.
STIM submitted a Form 144 notice reporting a proposed sale of Common stock associated with a restricted stock vesting event. The filing lists 46,289 shares tied to 03/18/2026 as the securities to be sold. The filing also discloses recent dispositions by Keith Sullivan of 40,976, 33,847, and 8,452 shares on 02/10/2026, 02/12/2026, and 02/26/2026, respectively.
Sullivan Keith J reported acquisition or exercise transactions in this Form 4 filing.
Neuronetics, Inc. reported that President and CEO Keith J. Sullivan received a grant of 112,500 shares of common stock. The shares were issued for no cash consideration upon satisfaction of performance criteria tied to performance-based restricted stock units. Following this award, Sullivan directly holds 1,637,213 shares of Neuronetics common stock. This is a compensation-related equity award rather than an open-market purchase.
Neuronetics, Inc. reported that its EVP, CLO and CS, William Andrew Macan, received an award of 33,750 shares of common stock. These shares were granted for no cash consideration after performance criteria tied to performance-based restricted stock units were satisfied. Following this equity award, his directly held common stock position increased to 913,275 shares, highlighting a compensation-related, non-market acquisition rather than an open-market purchase.
Pfanstiel Steven reported acquisition or exercise transactions in this Form 4 filing.
Neuronetics, Inc. reported that EVP, CFO and Treasurer Steven Pfanstiel received an equity grant of 25,000 restricted stock units (RSUs). Each RSU represents a right to receive one share of common stock, vesting in three equal annual installments beginning on March 17, 2027, subject to his continuous service. Following this award, Pfanstiel is shown as holding 845,212 shares of common stock directly.
Neuronetics, Inc. major shareholder Jorey Chernett reported an open-market purchase of 531,000 shares of common stock at a weighted average price of $1.16 per share. The filing notes the shares were bought in multiple trades between $0.91 and $1.31 per share. Following this transaction, Chernett directly owns 7,516,404 shares of Neuronetics common stock.
Neuronetics, Inc. reported that significant shareholder Jorey Chernett beneficially owns 6,985,404 shares of the company’s common stock. This Form 3 filing is an initial statement of holdings by a more than ten percent owner and does not reflect any new share transactions.